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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Mean age was 64 +/- 11.2 years, 84.4% males, 30.2% diabetics and 59.6%
had unstable angina at inclusion. 54.3% with 3 vessels and ULM, 1.8 +/- 0.3 Firebird-
2 per pt was implanted. Clinical success was accomplished in 100%. At discharge all
pts received DAPT. Complete 6 months follow-up results are reported in Table. In pts
with diabetes, Firebird-2 group also showed a beneﬁt in MACCE compared to ERACI
3-DES p¼0.02 and ERACI 3-CABG p¼0.04.6 months outcome
ERACI 4
ERACI 3-
DES
ERACI 3-
CABG
ERACI 4
vs ERACI
3-DES
ERACI 4
vs ERACI
3- CABG
N patients 225 225 225
Death 1 (0.4%) 6 (2.7%) 15 (6.7%) 0.05 <0.001
Myocardial
Infarction (MI)
1 (0.4%) 5 (2.2%) 14 (6.2%) 0.1 0.001
Non-fatal
Cerebrovascular
accident (CVA)
0 (0%) 1 (0.4%) 2 (0.9%) 0.31 0.15
Death/MI/CVA 2 (0.9%) 9 (4.0%) 31 (13.8%) 0.03 <0.001
Target vessel
revascularization
(TVR)
2 (0.9%) 13 (5.8%) 5 (2.2%) 0.004 0.25
MACCE (Death/
MI/CVA/TVR)
4 (1.8%) 17 (7.6%) 36 (16.0%) 0.004 <0.001Conclusions: At 6 months this multicenter and prospective registry showed that
Firebird 2 had a remarkable low incidence of MACCE and death/MI/CVA either
compared to CABG or 1st DES arms,Firebird 2 also had lower TVR rate than 1st
DES.
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Background: The ION Registry assessed clinical outcomes for the thin-strut, ION
(TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System
(Boston Scientiﬁc, Natick, MA) in unselected patients at 40 sites in the United
States. Two-year “real world” results with this stent have not been previously
reported.
Methods: This prospective, open-label registry enrolled 1120 consenting all-
comer patients treated with the ION stent for any indication at each site. Follow-
up was at discharge, 30 and 180 days, and annually to 5 years. The primary
endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients (ie,
patients who met the enrollment criteria for the pivotal PERSEUS trial; JACC
2010;56:264–71). Per protocol, the primary endpoint result from the ION registry
was also combined with the EU post-approval registry (TE-PROVE), which
enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations
(N¼1166).
Results: Among 1111 patients who received a study stent, most (70.3%, 781/
1111) were male, with a mean age of 64.111.0 years, and 316 were PERSEUS-
like. At 1-year, clinical follow-up or death were recorded in 92.1% (1023/1111).
The primary endpoint of cardiac death or MI at 1 year occurred in 2.1% (6/292)
of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the combined
analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%, which
was signiﬁcantly less than the prespeciﬁed performance goal of 7.6% (P<
0.001). Additional 1-year clinical endpoint rates were 9.4% (97/1028) MACE
(deﬁned as cardiac death, MI, TVR), 2.0% (21/1028) cardiac death (0.4% related
to ION stent), 3.0% (31/1028) MI (1.9% related to ION stent), 6.8% (70/1028)
TVR (4.9% related to ION stent), and 2.1% (22/1028) ARC deﬁnite/probable ST
(2.0% related to ION stent).
Conclusions: The 1-year results of the ION US Post-Approval Study conﬁrm the
safety and effectiveness of the ION stent for the treatment of coronary artery disease in
everyday clinical practice. Two-year overall results and results from selected subsets
of this real-world population (diabetes, small vessels, long lesions) will be available
for the ﬁrst time at TCT 2014.B168 JACC Vol 64/11/Suppl B j SeTCT-579
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Background: It remains unclear whether there are differences in the safety and ef-
ﬁcacy outcomes between Cobalt Chronium (CoCr-EES) and Platinum Chronium
everolimus-eluting stents (PtCr-EES).
Methods: From the Interventional Cardiology Research In-Cooperation Society-
Drug-Eluting Stents Registry, we identiﬁed 6065 consecutive patients who received
CoCr-EES (3080 patients) and PtCr-EES (2985 patients). We compared major
adverse cardiac events (MACE) which was deﬁned using a composite measure
consisting of death, nonfatal myocardial infarction, or target vessel revascularization
(TVR) with the use of propensity-score matching in the overall cohort according to
type of stents.
Results: At 2-years of clinical follow-up, the 2 study groups (2510 patients for each
propensity-score matched group) did not differ signiﬁcantly in crude risk of the
MACE (12.0% for CoCr-EES versus 11.6% for PtCr-EES; HR, 0.954; 95% CI, 0.81 –
1.13, p¼0.581). There was also no differences between the stent groups in the risks of
the individual component of death (HR, 1.083; 95% CI, 0.786 – 1.492, p¼0.624), MI
(HR, 0.972; 95% CI, 0.770 – 1.228, p¼0.812), and TVR (HR, 0.798; 95% CI, 0.598 –
1.065, p¼0.125). The risk of cerebrovascular event (HR, 0.914; 95% CI, 0.566 –
1.477, p¼0.714) and deﬁnite stent thrombosis (HR, 1.000; 95% CI, 0.290 – 3.454,
p¼1.000) were also similar between the two groups.Conclusions: The use of CoCr-EES and PtCr-EES showed similar rates of safety and
efﬁcacy outcomes with regard to death, MI, stent thrombosis and TVR.
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Background: The TE-PROVE post-market registry has enrolled 1014 patients at 37
sites in the EU to evaluate real-world clinical outcomes for patients receiving the
paclitaxel-eluting, platinum chromium TAXUS Element stent (Boston Scientiﬁc,
Natick, MA). This is the ﬁrst report of 2-year outcomes with the TAXUS Element
stent in everyday clinical practice.
Methods: The primary endpoint of overall and study stent-related target vessel failure
(TVF, deﬁned as cardiac death, and target vessel-related MI and reintervention [TVR])
at 1 year post-implantation was 6.0% (59/987), of which 3.7% (37/9874) was
considered related to the study stent (Tamburino et al, TCT 2013). Follow-up in TE-
PROVE will continue annually through 5 years. Secondary endpoints included the
components of TVF, all-cause mortality, and ARC deﬁnite/probable stent thrombosis.
An independent Clinical Events Committee adjudicated all events for relatedness to
the study stent.
Results: At baseline, 75.0% (760/1014) of patients were male, mean age was
65.110.8 years, 25.5% (259/1014) had medically treated diabetes, mean lesion
length was 19.812.0mm, and mean reference vessel diameter was 3.10.5 mm. At 2ptember 13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Registries
 2.25 mm
reference vessel
diameter
>2.25 but 2.75
mm reference vessel
diameter
Adjusted
p-value
Target Lesion Failure, % 11.2% 10.0% 0.59
Target Lesion
Revascularization, %
6.2% 4.5% 0.12
Cardiac Death / Target
Vessel Myocardial
Infarction, %
6.0% 6.3% 0.57
ARC deﬁnite/probable
stent thrombosis, %
1.2% 0.8% 0.26
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMyears, clinical follow-up or death occurred in 95.5% (968/1014) of patients. The 2-
year rate of TVF was 10.4% (101/972), of which 6.4% (62/972) was considered
related to the study stent. Cardiac death was 1.7% (7/987), with 0.2% considered
related to the study stent. Target vessel-related MI was 1.7% (17/972) (1.5% study
stent-related), and TVR was 8.3% (81/972) (5.7% study stent-related). ARC deﬁnite/
probable ST was 1.0% (10/972), with 0.9% (9/972) considered related to the study
stent. Two-year outcomes for subsets, including small vessels, long lesions, and
diabetes, will be available at the meeting.
Conclusions: At 2 years post-procedure, the thin-strut, platinum chromium, pacli-
taxel-eluting TAXUS Element stent continues to demonstrate good performance and
safety in everyday clinical practice.
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Background: Long term outcomes are imperative to conﬁrm safety of drug-eluting
stents. Only two randomized controlled trials have reported 2-year comparisons of
these stents, and no study has reported the 3-year long term clinical outcomes. This
study was performed to compare the long-term clinical outcomes of Xience V/Promus
everolimus-eluting stents (EES) with Resolute zotarolimus-eluting stents (ZES-R) in
“all-comer” cohorts.
Methods: The EXCELLENT and RESOLUTE-Korea registries prospectively
enrolled 3,056 patients treated with EES and 1,998 with ZES-R, respectively, without
exclusions. Stent-related composite outcomes (target lesion failure) and patients-
related composite events up to 3 years follow-up were compared in crude and pro-
pensity score matched analyses.
Results: Of 5054 patients, 3830 patients (75.8%) had off label indication (2217
treated with EES and 1613 treated with ZES-R). The stent-related outcome (189
[6.2%] vs. 127 [6.4%], p¼0.812) and the patient-related outcome (420 [13.7%] vs.
250 [12.5%], p¼0.581) did not differ between EES and ZES-R respectively at 3 year,
which was corroborated by similar results from the propensity score-matched cohort
(HR 0.92, 95% CI 0.70-1.20, p¼0.523 and 0.85, 95% CI 0.70-1.02, p¼0.081, for stent
and patient related outcomes, respectively) . The rate of deﬁnite or probable stent
thrombosis up to 3 years (22 [0.7%] vs. 10 [0.5%], p¼0.370) was also similar. The
rate of very late deﬁnite or probable stent thrombosis was very low and comparable
between the two stents (3 [0.1%] vs. 1 [0.1%], p¼0.657). In multivariate analysis,
chronic renal failure (adjusted HR 3.615, 95% CI 2.440-5.354, p< 0.001) and off label
indication (adjusted HR 1.782, 95% CI 1.169-2.718, p¼0.007) were the strongest
predictors of target lesion failure at 3-year.
Conclusions: In this robust real world registry with unrestricted use of EES and ZES-R,
both stents showed comparable safety and efﬁcacy at 3-year follow-up. Overall in-
cidences of target lesion failure and deﬁnite stent thrombosis, including very late stent
thrombosis, were low, even in the patients with off label indications, suggesting
excellent long term safety and sustained efﬁcacy of both types of second generation
DES.
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Background: Limited clinical data is available in patients who underwent percuta-
neous coronary intervention (PCI) with drug eluting stents in very small vessels
(reference vessel diameter [RVD]  2.25 mm).
Methods: We examined the outcomes of patients who underwent PCI using Reso-
luteTM zotarolimus-eluting stent (R-ZES) in the pooled RESOLUTE program in
vessels with RVD 2.25 mm and compared them to those of patients with RVD
>2.25 but 2.75 mm. The RESOLUTE global clinical program includes: RESO-
LUTE First-in-Human, RESOLUTE All Comers (R-AC), RESOLUTE International,
RESOLUTE US, RESOLUTE Japan, RESOLUTE Japan Small Vessel, RESOLUTEJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteAsia, RESOLUTE China, and Resolute China Registry. Target Lesion Failure (TLF)
was the composite of death from cardiac causes, target vessel myocardial infarction
(TV-MI), and target lesion revascularization (TLR). The incidence of clinical events
was calculated using the Kaplan Meier. Given differences in baseline characteristics,
patients were matched by propensity scores based on 24 baseline variables and
adjusted p-values are provided.
Results: A total of 1203 subjects with RVD 2.25 mm RVD and 2773 subjects with
RVD >2.25 but 2.75 mm were treated with R-ZES. Compared with patients with
RVD >2.25 but 2.75 mm, patients with RVD 2.25 mm had more complex
baseline characteristics including prior PCI (33% vs. 26%, p< 0.001) and history of
hypertension (78% vs. 72%, p< 0.001), respectively. However, there was no signif-
icant difference in TLF, TLR, CD/TV-MI or ARC deﬁnite/probable ST at 3 years
(Table).
Conclusions: No increased risk is associated with the use of R-ZES in very small
vessels (RVD2.25 mm) compared with use in small vessels between 2.25 and 2.75
mm. Low rates of clinical events were observed through long-term follow-up in both
groups. Submitted on behalf of the RESOLUTE Global Clinical ProgramTCT-583
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Background: There is still uncertainty about the durability of the results of drug-
eluting stents (DES) in real-world complex patients. We sought to provide the
longest clinical follow-up data on outcomes of unselected patients treated solely
with DES.
Methods: The DESIRE registry is a prospective, single-center registry encom-
passing all consecutive patients treated solely with DES since May 2002. The
primary goal is the very long-term occurrence of MACE and stent thrombosis
(ST). Patients were clinically followed at 1, 6 and 12 months and then annually. A
multivariate model was built to determine independent predictors of MACE, TLR
and ST.
Results: A total of 5,500 patients were included. The mean age was 64  11 years.
DM was detected in 29.7% and 44.8% presented with acute coronary syndrome. SVG
lesions and STEMI represented 6% and 12% of the cohort, respectively. Follow-up
was obtained in 98.2% of the patients (median 5.6 years). Currently, 79.6% of the
population is free of any MACE. TVR was performed in 5.3% of the patients. Q-wave
MI rate was only 1.7% while total ST rate was 1.9%. The majority of deﬁnite ST cases
occurred between the 1st and 3rd years. Independent predictors of MACE were
treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p¼ 0.001), multivessel disease (HR
1.39; 95% CI, 1.03 to 1.87, p< 0.001), residual stenosis (HR 1.3; 95% CI, 1.1 to 1.5,
p¼ 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p¼ 0.006) and renal insufﬁciency (HR
1.5; 95% CI, 1.34 to 1.81, p¼ 0.004). Independent predictors of ST were PCI for
STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p¼ 0.013), stent length (HR 1.8; 95% CI, 1.09 to
3.02, p¼0.023), moderate/severe calciﬁcation at lesion site (HR 2.38; 95% CI, 1.34 to
4.23, p¼0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 1.06,
p¼0.003).
Conclusions: In our single center experience, the use of DES was associated with
very long-term safety and effectiveness with acceptable low rates of adverse clinical
events, including ST.nts - Drug-eluting: Registries B169
